How well this hotline does its job remains to be seen. Part of having a hotline is having people on the other end who are trained to separate out what is of immediate concern and what is of lesser concern.

Now the Health Department needs to publicize its existence wherever it can. Otherwise you have a hotline nobody knows about.

I think the issue here is that you want the labeling to reflect the most current science. But at the same time you wouldn't want to change it to overplay the benefit of a single study and downplay the body of all other research.

I don't think it's a drug safety board...The model is bad, the name is bad. Why can't there be an audience?

The department's promise to expedite the investigation of egregious complaints may save lives.

The issue of drug treatment of attention deficit disorder in children has been a controversial one without this issue of cardiovascular risk too. It adds another concern to what will certainly be an interesting conversation.